Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BECLOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BECLOVENT.
ARMONAIR RESPICLICK vs BECLOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway hyperresponsiveness, and suppresses immune cell activity.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
2 inhalations (84 mcg) twice daily; not to exceed 10 inhalations (420 mcg) per day. Administered via oral inhalation using a metered-dose inhaler.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life of beclomethasone dipropionate is 0.5 hours; active metabolite beclomethasone-17-monopropionate has half-life of 2.7 hours; clinically, systemic effects persist for 12-24 hours.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (60-70%) and urine (10-15%); less than 5% unchanged drug in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid